Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2871485 | 1.00 | MAPT (0.59) | MAPTRXFP1EPHX2HDAC3HDAC4 | |
| SCHEMBL8984468 | 1.00 | MAPT (0.59) | MAPTRXFP1EPHX2HDAC3HDAC4 | |
| SCHEMBL8984382 | 1.00 | MAPT (0.59) | MAPTRXFP1EPHX2HDAC3HDAC4 | |
| SCHEMBL6422109 | 1.00 | MAPT (0.59) | MAPTRXFP1EPHX2HDAC3HDAC4 | |
| SCHEMBL2867823 | 1.00 | MAPT (0.59) | MAPTRXFP1EPHX2HDAC3HDAC4 | |
| SCHEMBL1008067 | 1.00 | MAPT (0.59) | MAPTRXFP1EPHX2HDAC3HDAC4 | |
| SCHEMBL1007119 | 1.00 | MAPT (0.59) | MAPTRXFP1EPHX2HDAC3HDAC4 | |
| SCHEMBL5508985 | 1.00 | MAPT (0.59) | MAPTRXFP1EPHX2HDAC3HDAC4 | |
| SCHEMBL712393 | 0.98 | MAPT (0.56) | MAPTRXFP1EPHX2HDAC3HDAC4 | |
| SCHEMBL31482293 | 0.97 | MAPT (0.56) | MAPTRXFP1EPHX2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025134071-A1 | MALIC AND GLUTARIC ACID BASED IONIZABLE LIPIDS | SANOFI (FR) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| CN-116368146-A | Novel ligands for asialoglycoprotein receptors | 赛诺菲 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022084331-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI (FR) | 2022-04-28 | — | — | WO | disclosed |
| US-10866230-B2 | Fiber coated nanopores | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-12-15 | — | — | US | disclosed |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-1021423-A1 | MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF$g(a) SECRETION | Abbott Laboratories (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0964851-A1 | C-TERMINAL KETONE HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES AND TNFA SECRETION | Abbott Laboratories (US) | 1999-12-22 | — | — | EP | disclosed |
| US-5985911-A | COMBATTING DISEASE STATES INVOLVING TISSUE DEGENERATIVE PROCESSES I.E, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR | ABBOTT LABORATORIES (US) | 1999-11-16 | — | — | US | disclosed |
| US-5952320-A | USEFUL IN THE TREATMENT OF DISEASES IN WHICH MATRIX METALLOPROTEINASE PLAY A ROLE; MATRIX METALLOPROTEINASE INHIBITING COMPOSITIONS | ABBOTT LABORATORIES (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1998030541-A1 | C-TERMINAL KETONE HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES AND TNFA SECRETION | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1998030551-A1 | MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNFα SECRETION | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| US-5618844-A | MATRIX METALLOPROTEINASE INHIBITOR | SANOFI S.A. (FR) | 1997-04-08 | — | — | US | disclosed |
| US-5514716-A | MATRIX METALLOPROTEINASE INHIBITORS, ANTIARTHRITIC | STERLING WINTHROP, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| US-5153214-A | Treating cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0493324-A1 | Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof | CIBA-GEIGY AG (CH) | 1992-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | MAPT 2060/4885RXFP1 4587/4885EPHX2 4386/4885 |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | MAPT 3945/4885RXFP1 1765/4885EPHX2 1793/4885 |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | MAPT 4869/4885RXFP1 1114/4885EPHX2 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.